Navilyst Medical Announces the Launch of its Charter™ Guidewire

Share Article

Navilyst Medical announced today the broadening of its Embolization Portfolio with the U.S. launch of its new Charter Guidewire. The core-to-tip features of the Charter Guidewire are designed to provide clinicians with the control and precision they require during peripheral vascular procedures.

Charter™ Guidewire

Navilyst Medical announced today the broadening of its Embolization Portfolio with the U.S. launch of its new Charter Guidewire. The core-to-tip features of the Charter Guidewire are designed to provide clinicians with the control and precision they require during peripheral vascular procedures.

"We are excited to broaden our Embolization Portfolio," said Chairman and CEO, Ron Sparks. "Together the strength of our R&D Team and their ability to harness the latest technologies allow us to bring products to market providing physicians with the latest advancements to better treat their patients."

The Charter Guidewire is designed to resist deformation and provide precise torque to facilitate placement and distal access through the most tortuous anatomy. Its one-piece construction of a stainless steel ground core wire eliminates abrupt transitions and reduces core twisting during rotation, enabling torque transmission along the central axis. The core-to-tip design provides pushability with precise steering, tip control and torqueability.

Additionally, the Charter Guidewire's PTFE and GLYCE™ Hydrophilic Coatings reduce friction and increase trackability. A primer effect is created through a tie layer adherence to the polyurethane jacket enhancing durability. The tungsten and platinum coil tip, highly visible under fluoroscopy, is less traumatic and enhances shapeability and shape retention.

Embolotherapy continues to be a growing area of importance for a variety of specialties including Interventional Oncology. In these procedures, physicians can not only reach the targeted site but are able to deliver cancer treatments directly to the tumor without damaging surrounding healthy tissue as well as reduce significant side effects. Embolization devices will continue to be an integral part of these leaps forward.    

About Navilyst Medical

Navilyst Medical Inc., headquartered in Marlborough, MA, is a leading provider of innovative solutions for image-guided interventions designed to deliver superior outcomes and reduce healthcare costs for medical professionals and their patients. Its breakthrough devices include BioFlo™ PICCs, available for sale in Canada and Europe, and PICCs and Ports with PASV® Valve Technology, Xcela® Power Injectable PICCs and world-leading NAMIC® Fluid Management products. The Company distributes its products globally and has its U.S. manufacturing facility in Glens Falls, NY. For more information, please visit: http://www.navilystmedical.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jill Robinson
Navilyst Medical
(508) 658-7990
Email >
Visit website